ATLANTA — Jan. 4, 2019 — In 2018, Bako Diagnostics (BakoDx) continued a long tradition of supporting the podiatric medical community.
These efforts and commitments will continue in 2019.
To view events for 2019, please click here.
Watch this video recap of where BakoDx was present in 2018.
ATLANTA/BOSTON—October 10, 2018— Bako Diagnostics and StrataDx announce a strategic relationship. The parent company of Bako Diagnostics has acquired StrataDx, a leading U.S. dermatopathology and oral pathology laboratory, serving physicians across the U.S.
While maintaining separate clinical laboratories, the common ownership allows the companies to operate more efficiently and bring their respective core services to broader markets, while continuing to serve their customers independently.
“We are pleased to join with Bako Diagnostics in this strategic relationship,” stated Lisa Cohen, MD, CEO of StrataDx. “We will continue to provide our customers with the same high quality dermatopathology, oral pathology, surgical pathology and clinical services they have come to expect without interruption. We also look forward to heightening our focus on the dermatology market while expanding our customer base.” Dr. Lisa Cohen will continue to lead the group at StrataDx and will work with the leadership team at Bako to help further the mission of high quality and service that both organizations have always valued.
“We are excited to partner with StrataDx in providing the highest quality clinical laboratory and pathology services to our respective customers,” stated Ted Hull, CEO, Bako Diagnostics. “Bako will continue to focus on serving our customers in the podiatric market while benefitting from our affiliation with one of the top dermatopathology and oral pathology labs in the country.”
ABOUT BAKO DIAGNOSTICS
Bako Diagnostics is a leading provider of diagnostic and therapeutic services for the Podiatric Medical Community with a unique focus on pathology of the lower extremity. Bako’s comprehensive testing menu includes ENFD Analysis, Mass Spectrometry, rapid identification of bacteria from culture specimens, and Molecular Genetics for the detection and identification of micro-organisms and as a diagnostic aid in certain pathologic diagnoses. Bako’s in-network services are available through its more than 250 million covered lives, including all five national health plans and fully compliant patient-friendly billing policies. Over the past nine years, Bako has evolved into one of the podiatric profession’s principal sources of educational sponsorship. For more information, visit bakodx.com.
ABOUT STRATADX
StrataDx is a national diagnostic laboratory located in Lexington, Massachusetts dedicated to providing best-in-class pathology services to save lives. Led by dermatopathology experts, StrataDx provides advanced diagnostics for a wide range of skin conditions including melanocytic and soft tissue lesions, dermatoses, and lymphomas. Board-certified oral pathologists represent decades of expertise across a wide range of clinical specialties. StrataDx is considered a leader in testing for the dermatology market. For more information, visit stratadx.com.
ATLANTA — July 11, 2018 — Bako Diagnostics (BakoDx), the leader in nail dystrophy diagnostic testing, announced the availability of its expanded molecular test to include detection of the causative agent of green nail syndrome.
Dr. Shari Lipner, assistant professor of dermatology at Weill Cornell Medicine, whose specialty is nail diseases, said she sees a lot of patients with onychomycosis along with another common problem — Pseudomonas aeruginosa — otherwise known as Green Nail Syndrome.
“Pseudomonas nail infection is a very frustrating condition for patients because it’s often misdiagnosed,” Dr. Lipner said. “Having a molecular test to help with the diagnosis is very helpful, so patients can get the treatment they need.”
BakoDx’s onychodystrophy panel was enhanced to detect Pseudomonas aeruginosa, with clinically relevant results in as little as 24 hours[1].
Green nail syndrome, characterized by a greenish black discoloration of the nail, is caused by the growth and colonization of P. aeruginosa: the most common bacterial nail infection. Predisposing conditions can include: onycholysis, onychomycosis, diabetes mellitus, as well as occupations where the feet are frequently exposed to wet conditions or damp environments.
“The addition of P. aeruginosa to our onychodystrophy panel enables clinicians to identify one of the non-fungal causes of infectious onychodystrophy and treat it appropriately. Expansion of the nail dystrophy assay empowers clinicians with clinically relevant results to support appropriate antimicrobial therapy to improve patient outcomes,” said Dr. Wayne L. Bakotic, Dermatopathologist and BakoDx Co-Founder.
For more information, visit bakodx.com/green-nail-syndrome or call 855-422-5628.
Media Contact:
Aldo Nahed
Communications@bakodx.com
470-695-3643 Ext. 283
[1] Pseudomonas aeruginosa testing not currently available in the State of New York.
ABOUT BAKO DIAGNOSTICS
Bako Diagnostics is a provider of diagnostic and therapeutic services for the Podiatric Medical Community with a unique focus on pathology of the lower extremity. Bako’s comprehensive testing menu includes ENFD Analysis, Mass Spectrometry, for rapid identification of bacteria from culture specimens, and Molecular Genetics for the detection of micro-organisms and as a diagnostic aid in certain pathologic diagnoses. Bako’s in-network services are available through its more than 250 million covered lives, including all five national health plans and fully compliant patient-friendly billing policies. Over the past nine years, Bako has evolved into one of the podiatric profession’s principal sources of educational sponsorship.
ATLANTA. Feb. 26, 2018 – Bako Diagnostics, a podiatry-focused clinical laboratory and products company, announced today that they have formed a Podiatric Advisory Board to assist in implementing the Company’s current plans and identifying means to capitalize on future growth opportunities. The board will provide guidance in navigating, innovating, and growing the organization to carry out its mission of providing the highest quality laboratory services and products customized for the podiatric medical profession.
The Advisory Board, which is comprised of distinguished podiatrists, educators, innovators, and scholars, includes Allen M. Jacobs, DPM (St. Louis, MO), Jeffrey D. Lehrman, DPM (Springfield, PA) and William P. Scherer, DPM, MS (Delray Beach, FL).
“We are pleased to have this group of talented thought leaders who support our commitment to the Podiatric Medical and Surgical Community,” stated Wayne L. Bakotic, DO, who will serve as Chairman of the Advisory Board. “We look forward to interacting with them and benefitting from their opinions, advice and guidance. It is anticipated that the Advisory Board may further expand to include additional members as we grow to suit the needs of our medical partners.”
Bako’s Podiatric Advisory Board will help the Company evolve processes, fortify offerings, and continue in educational endeavors to support the medical professionals they serve.
ABOUT BAKO DIAGNOSTICS
Bako Diagnostics is a provider of diagnostic and therapeutic services for the Podiatric Medical Community with a unique focus on pathology of the lower extremity. Bako’s comprehensive testing menu includes ENFD Analysis, Mass Spectrometry, for rapid identification of bacteria from culture specimens, and Molecular Genetics for the detection of micro-organisms and as a diagnostic aid in certain pathologic diagnoses. Bako’s in-network services are available through its more than 250 million covered lives, including all five national health plans and fully compliant patient-friendly billing policies. Over the past nine years, Bako has evolved into one of the podiatric profession’s principal sources of educational sponsorship.
ATLANTA. Feb. 26, 2018 – Bako Diagnostics, a podiatry-focused clinical laboratory and products company, announced appointments to the Bako Clinical Consultant Team. This Team will represent Bako Diagnostics at various local, state, and national medical conferences, providing educational sessions and workshops.
The Clinical Consultant Team, which is comprised of some of the most knowledgeable, accomplished, and dedicated podiatrists within the profession, includes:
Javan S. Bass, DPM
Lithonia, Georgia
Robert M. Conenello, DPM
Orangeburg, New York
Andrew H. Cohen, DPM
Saginaw, Michigan
Brandon J. Hawkins, DPM
Bakersfield, California
LeRoy J. Kelley, III, DPM
Norwood, Massachusetts
Jeffrey D. Lehrman, DPM
Springfield, Pennsylvania
Marc A. Lederman, DPM
West Hartford, Connecticut
Allen M. Jacobs, DPM
Saint Louis, Missouri
William P. Scherer, DPM, MS
Delray Beach, Florida
Lauren A. Schwartz, DPM
Manhasset, New York
Tracey C. Vlahovic, DPM
Philadelphia, Pennsylvania
Daniel L. Waldman, DPM
Asheville, North Carolina
“We feel privileged to partner with this fine group of podiatric physicians who enhance and improve our educational endeavors with their respective talent and expertise in the field of podiatric medicine and surgery,” stated Shawna Shapero, Vice President, Corporate and Professional Relations. “These appointments will serve to fortify our educational outreach within the profession. We plan to expand our Clinical Consultant Team to include additional members.”
ABOUT BAKO DIAGNOSTICS
Bako Diagnostics is a provider of diagnostic and therapeutic services for the Podiatric Medical Community with a unique focus on pathology of the lower extremity. Bako’s comprehensive testing menu includes ENFD Analysis, Mass Spectrometry, for rapid identification of bacteria from culture specimens, and Molecular Genetics for the detection of micro-organisms and as a diagnostic aid in certain pathologic diagnoses. Bako’s in-network services are available through its more than 250 million covered lives, including all five national health plans and fully compliant patient-friendly billing policies. Over the past nine years, Bako has evolved into one of the podiatric profession’s principal sources of educational sponsorship.
ATLANTA. Dec. 15 /PRNewswire/ – Bako, a podiatry-focused clinical laboratory and products company, announced today the launch of its new website-bakodx.com, new company name and newly designed company logo. As a partner and advocate to the podiatric community, the website is designed to be a leading source of education, innovation and insight for podiatrists. The company’s new name and new logo reflects the evolution of the company from Bako Integrated Physician Services to Bako Diagnostics.
“We are excited to launch this new site that provides user-friendly access to all of Bako services, products and learning materials.” stated Larry McCarthy, Bako’s CEO. “We will continue to modify this site as the needs of podiatrists evolve and new tests and technologies are introduced by our company.”
The new site has been optimized to provide a great user experience across all digital devices, including desktop and mobile. It includes a newly updated learning center, an educational resource for podiatrists and their staff, and a simple means for podiatrists to collaborate with Bako’s team of pathologists.
“Our new company name and logo, demonstrates the expansion of our laboratory services into the molecular diagnostics arena.” said Dan Spragle, President and COO. “We will continue to grow services while still providing podiatrists with our innovative and industry-leading pathology tests on which they have come to rely.”
Bako, headquartered in Alpharetta, GA with over 230 employees, serves as a specialty testing lab for clinicians of the lower extremity, providing their patients with easy access to affordable diagnostic testing and treatments.
Bako is proud to invest in the future of podiatry by funding a series of two-week fellowships in podiatric dermatology at their laboratory facility. Interested candidates can sign-up on the new website https://bakodx.com/learning-center/podiatric-dermatology-fellowship-program/.
ABOUT BAKO DIAGNOSTICS
Bako Diagnostics is a provider of diagnostic and therapeutic services with a unique focus on pathology of the lower extremity. Bako’s comprehensive testing menu includes ENFD Analysis, Mass Spectrometry, for rapid identification of bacteria from culture specimens, and Molecular Genetics for the detection of micro-organisms and as a diagnostic aid in certain pathologic diagnoses. Bako’s in-network services are available through its more than 200 million covered lives, including all five national health plans and fully compliant patient-friendly billing policies. Over the past nine years, Bako has evolved into one of the podiatric profession’s principal sources of educational sponsorship.